OM DETTA AVSNITT

Engelsk
USA

UTSKRIFT 🔗

SÖK TIDIGARE AVSNITT

Sök efter tidigare avsnitt från IBCD 2016.

ANDRA EPISODER I DENNA PODCAST

Dr Golfinopoulos meets with ecancertv at IBCD 2016 to discuss SPECTA: a screening platform that sought to encourage patients to participate in clinical trials. He describes how regulatory involvement in trial design and drug design could be streamlined, and the issue of reimbursement for personali…
Dr Malik speaks with ecancertv at IBCD 2016 to discuss the work of the National Cancer Institute in recruiting patients to clinical trials when subtyping limits disease-wide enrollment. She describes how 'exceptional responders' can be referred to the NCI for genotyping, and schemes to match patie…
Dr Schneider speaks with ecancertv at IBCD 2016 about the regulatory checkpoints to be passed in the development of assays. He highlights the difference in reproducibility and robustness of research and clinical assays, the clinical utility of validated biomarkers, and how beginning assay developm…
Dr Gerstung speaks with ecancertv at IBCD 2016 about genetic analysis of AML patients that has contributed to a predictive model for treatment risk and outcomes. He describes how modelling can be improved with wider data gathering, across populations and tumour types, though this faces the risk of…
Ansvarsfriskrivning: Podcasten och konstverket som är inbäddat på den här sidan är från ecancer.org, som är dess ägares egendom och inte anslutet till eller godkänt av Listen Notes, Inc.